Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02283359 · ClinicalTrials.gov registry record · Phase 1
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02283359 is a Phase 1 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 3 participants.
The verdict
NCT02283359, a Phase 1 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The main purpose of this study is to see whether the combination of selinexor (KPT-330) and irinotecan can help people with esophageal or stomach cancer. Researchers also want to find out if the combination of selinexor (KPT-330) and irinotecan is safe and tolerable.
Interventions
- DRUG Selinexor
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02283359
The ClinicalTrials.gov registry entry for NCT02283359 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selinexor is the first listed.
NCT02283359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02283359 about?
NCT02283359 is a clinical study titled "Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus". The main purpose of this study is to see whether the combination of selinexor (KPT-330) and irinotecan can help people with esophageal or stomach cancer. Researchers also want to find out if the combination of selinexor (KPT-330) and irinotecan is safe and tolerable.
What is the current status of trial NCT02283359?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02283359?
The interventions under investigation include: Selinexor (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT02283359?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.